A Phase 2, Open-Label, 2-C Cohort Study of INCB050465, A P13K@ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Clinical Trial Grant
Awarded By
Incyte Corporation
Start Date
June 6, 2017
End Date
June 9, 2020
Awarded By
Incyte Corporation
Start Date
June 6, 2017
End Date
June 9, 2020